Replies to post #155812 on Biotech Values

[DewDiligence]

Curious error in SA transcript of BMY CC:

http://seekingalpha.com/article/1131001-bristol-myers-squibb-s-ceo-discusses-q4-2012-results-earnings-call-transcript

(Lamberto Andreotti, CEO): Eliquis has a real differentiated profile, and we were very encouraged to see the approvals in different parts of the world, reflects the risk rate action versus Warfarin in all three important outcomes of strong reduction, nasal bleeding and all because of that. So good clinical data and labels reflecting that clinical data.

The word nasal should be major, which is not that close in sound.